DexCom Inc - Asset Resilience Ratio
DexCom Inc (DXCM) has an Asset Resilience Ratio of 19.55% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is DexCom Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how DexCom Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see DexCom Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down DexCom Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore DXCM long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.30 Billion | 19.55% |
| Total Liquid Assets | $1.30 Billion | 19.55% |
Asset Resilience Insights
- Good Liquidity Position: DexCom Inc maintains a healthy 19.55% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
DexCom Inc Industry Peers by Asset Resilience Ratio
Compare DexCom Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
TransMedics Group Inc
NASDAQ:TMDX |
Medical Devices | 0.00% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581 |
Medical Devices | 18.80% |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580 |
Medical Devices | 10.74% |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273 |
Medical Devices | 34.29% |
Annual Asset Resilience Ratio for DexCom Inc (2005–2025)
The table below shows the annual Asset Resilience Ratio data for DexCom Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.05% | $1.08 Billion | $6.34 Billion | -13.38pp |
| 2024-12-31 | 30.43% | $1.97 Billion | $6.48 Billion | -4.01pp |
| 2023-12-31 | 34.44% | $2.16 Billion | $6.26 Billion | +0.80pp |
| 2022-12-31 | 33.64% | $1.81 Billion | $5.39 Billion | -0.38pp |
| 2021-12-31 | 34.03% | $1.68 Billion | $4.93 Billion | -10.03pp |
| 2020-12-31 | 44.05% | $1.89 Billion | $4.29 Billion | -1.34pp |
| 2019-12-31 | 45.39% | $1.09 Billion | $2.40 Billion | +32.42pp |
| 2018-12-31 | 12.97% | $248.60 Million | $1.92 Billion | +1.13pp |
| 2017-12-31 | 11.85% | $107.10 Million | $904.10 Million | +4.60pp |
| 2016-12-31 | 7.25% | $29.20 Million | $402.80 Million | -2.72pp |
| 2015-12-31 | 9.97% | $29.10 Million | $292.00 Million | +3.57pp |
| 2014-12-31 | 6.39% | $11.80 Million | $184.60 Million | -2.91pp |
| 2013-12-31 | 9.31% | $11.40 Million | $122.50 Million | -29.00pp |
| 2012-12-31 | 38.30% | $40.60 Million | $106.00 Million | -27.57pp |
| 2011-12-31 | 65.87% | $79.36 Million | $120.47 Million | +11.15pp |
| 2010-12-31 | 54.72% | $42.22 Million | $77.16 Million | +2.66pp |
| 2009-12-31 | 52.06% | $24.44 Million | $46.95 Million | +19.67pp |
| 2008-12-31 | 32.39% | $14.37 Million | $44.37 Million | -20.95pp |
| 2007-12-31 | 53.34% | $41.21 Million | $77.26 Million | -2.96pp |
| 2006-12-31 | 56.30% | $36.34 Million | $64.55 Million | +32.89pp |
| 2005-12-31 | 23.41% | $13.28 Million | $56.73 Million | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more